Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S). Abstract #1702

Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.
Aim(s): We performed retrospective analysis of pts with pNETs treated with E or S. Previously these pts have not been treated with either of these drugs.
Materials and methods: 20 pts with progressive pNETs (G1,G2) were treated with E and 16 pts with S 37,5 mg or 50mg dose regimen. All pts were on treatment with long acting octreotide. The mean age was 47 years in E group and 53 in S group. Most pts had liver metastases – 17/20 (85%) in E group and 15/16 (93%) in S group, regional l/nodes – in 6/20 (30%) and 6/16 (38%) and not regional l/nodes in – 4/20 (20%) and 4/16 (25%) pts respectively. Only 4 pts in each group were heavily pretreated with 3 or more lines of chemotherapy. G1 tumor was in 3 pts (E group) and no one in S group. Cytoreductive surgery was performed in 8 (40%) pts (E) and 9 (56%) pts (S).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Vera Gorbunova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1294 The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience.
Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova
#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova
#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Alexander Kuzminov